Ocular Therapeutix, Inc. $OCUL Shares Acquired by Summer Road LLC

Summer Road LLC boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 6.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,879,825 shares of the biopharmaceutical company’s stock after buying an additional 771,270 shares during the quarter. Ocular Therapeutix accounts for approximately 70.8% of Summer Road LLC’s investment portfolio, making the stock its largest position. Summer Road LLC owned approximately 0.05% of Ocular Therapeutix worth $100,622,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of OCUL. Steward Partners Investment Advisory LLC raised its position in Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Ocular Therapeutix during the 4th quarter valued at about $31,000. Hilton Head Capital Partners LLC boosted its position in shares of Ocular Therapeutix by 30.4% during the 1st quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,053 shares in the last quarter. Atlas Capital Advisors Inc. bought a new position in shares of Ocular Therapeutix during the 4th quarter valued at about $61,000. Finally, KBC Group NV acquired a new position in shares of Ocular Therapeutix in the 4th quarter worth approximately $78,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,156 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total value of $173,479.20. Following the transaction, the insider owned 2,597,170 shares in the company, valued at $21,296,794. This represents a 0.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 28,999 shares of company stock valued at $237,792. 3.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OCUL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Needham & Company LLC restated a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, May 5th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target (up from $21.00) on shares of Ocular Therapeutix in a report on Thursday, June 18th. Chardan Capital upped their price target on Ocular Therapeutix from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average target price of $25.11.

Ocular Therapeutix Stock Down 0.8%

Shares of Ocular Therapeutix stock opened at $9.82 on Wednesday. Ocular Therapeutix, Inc. has a 1 year low of $6.23 and a 1 year high of $16.44. The company has a market cap of $2.15 billion, a P/E ratio of -6.73 and a beta of 0.89. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12. The stock has a 50-day moving average price of $9.11 and a 200 day moving average price of $9.72.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.